| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Clinical Trial |
Dept of Clinical Therapeutics, Medical School, University of Athens, Greece. mdimop@med.uoa.gr
Osteonecrosis of the jaw (ONJ) has been associated with the use of pamidronate and zoledronic acid. ONJ was assessed prospectively since July 2003 in 202 patients with multiple myeloma (MM) who received bisphosphonates since April 1995. Fifteen patients (7.4%) developed ONJ. The median time of exposure to bisphosphonates was 39 months for patients with ONJ compared to 28 months (p=0.048) for patients with no ONJ. The cumulative hazard of developing ONJ was significantly higher in patients treated with zoledronic acid alone than in those treated with pamidronate alone/pamidronate+zoledronic acid/zoledronic acid+ibandronate sequentially (1% at 1 year and 15% at 4 years vs. 0% and 5%, p=0.003). In conclusion, the risk of ONJ is increased with time of exposure and probably with the use of zoledronic acid.
This article has been cited by other articles:
|
|
 |
|
  M. E. Sarasquete, R. Garcia-Sanz, L. Marin, M. Alcoceba, M. C. Chillon, A. Balanzategui, C. Santamaria, L. Rosinol, J. de la Rubia, M. T. Hernandez, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis Blood, October 1, 2008; 112(7): 2709 - 2712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Khan Bisphosphonate-associated osteonecrosis of the jaw Can Fam Physician, July 1, 2008; 54(7): 1019 - 1021. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Raje, S.-B. Woo, K. Hande, J. T. Yap, P. G. Richardson, S. Vallet, N. Treister, T. Hideshima, N. Sheehy, S. Chhetri, et al. Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw Clin. Cancer Res., April 15, 2008; 14(8): 2387 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. B. Dodson, N. S. Raje, P. A. Caruso, and A. E. Rosenberg Case 9-2008 -- A 65-Year-Old Woman with a Nonhealing Ulcer of the Jaw N. Engl. J. Med., March 20, 2008; 358(12): 1283 - 1291. [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Dass and P. F.M. Choong Zoledronic acid inhibits osteosarcoma growth in an orthotopic model Mol. Cancer Ther., December 1, 2007; 6(12): 3263 - 3270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Petrucci, C. Gallucci, A. Agrillo, M. C. Mustazza, and R. Fo Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients Haematologica, September 1, 2007; 92(9): 1289 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-B. Woo and D. H. Solomon Bisphosphonate Therapy for Cancer and Prevalence of Inflammatory Jaw Conditions J Natl Cancer Inst, July 4, 2007; 99(13): 986 - 987. [Full Text] [PDF]
|
|
|
|
|
|
G. S. Wilkinson, Y.-F. Kuo, J. L. Freeman, and J. S. Goodwin Intravenous Bisphosphonate Therapy and Inflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis J Natl Cancer Inst, July 4, 2007; 99(13): 1016 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Kyle, G. C. Yee, M. R. Somerfield, P. J. Flynn, S. Halabi, S. Jagannath, R. Z. Orlowski, D. G. Roodman, P. Twilde, and K. Anderson American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma J. Clin. Oncol., June 10, 2007; 25(17): 2464 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Aguiar Bujanda, U Bohn Sarmiento, M. Cabrera Suarez, and J Aguiar Morales Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis Ann. Onc., March 1, 2007; 18(3): 556 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie, and J. D. Shaughnessy Jr Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood, March 1, 2007; 109(5): 2106 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D Krueger, P. M West, M. Sargent, A. E Lodolce, and A S. Pickard Bisphosphonate-Induced Osteonecrosis of the Jaw Ann. Pharmacother., February 1, 2007; 41(2): 276 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tosi, E. Zamagni, D. Cangini, P. Tacchetti, F. Di Raimondo, L. Catalano, A. D'Arco, S. Ronconi, C. Cellini, M. Offidani, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood, December 15, 2006; 108(12): 3951 - 3952. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mehrotra and S. Ruggiero Bisphosphonate Complications Including Osteonecrosis of the Jaw Hematology, January 1, 2006; 2006(1): 356 - 360. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
